Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research> G Sachs: WuXi AppTec (02359.HK) 1Q26 Results Far Exceed Expectations; Maintains Buy Rating
Recommend 3 Positive 0 Negative 2 |
||||
|
||||
|
A research report by G Sachs stated that WuXi AppTec (02359.HK) delivered strong results for 1Q26, with both revenue and profit far exceeding the brokers and the markets expectations. During the period, revenue rose 28.8% YoY to RMB12.44 billion, of which revenue from continuing operations increased 39.4% YoY, mainly driven by YoY growth of 43.7% in the WuXi Chemistry business and 27.4% in the WuXi Testing business. The broker noted that in February this year, it upgraded WuXi AppTec to Buy, reflecting stronger confidence in the companys earnings outlook for 2026 and increasingly clear growth prospects for 2027. In early April, the stock was added to the Conviction List. The 1Q26 results further reinforced its investment thesis, supported by the companys solid order backlog, continued capacity expansion in the TIDES business, accelerating growth momentum in small-molecule drug development and commercialization, and oral small-molecule GLP-1 inhibitor projects increasingly becoming key growth drivers starting from 2026. As late-stage R&D projects and commercialized assets continue to increase, these factors are expected to further enhance visibility of mid-term revenue and earnings. G Sachs set a TP of HKD149.7 for WuXi AppTecs H shares, based on a 12-month forward price-to-earnings ratio of 19x. It also set a TP of RMB137.3 for WuXi AppTec (603259.SH) A shares. Both share classes are rated Buy and included on the Conviction List. (hc/ad) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
